These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

398 related items for PubMed ID: 20500147

  • 21. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
    Kalincik T, Horakova D, Spelman T, Jokubaitis V, Trojano M, Lugaresi A, Izquierdo G, Rozsa C, Grammond P, Alroughani R, Duquette P, Girard M, Pucci E, Lechner-Scott J, Slee M, Fernandez-Bolanos R, Grand'Maison F, Hupperts R, Verheul F, Hodgkinson S, Oreja-Guevara C, Spitaleri D, Barnett M, Terzi M, Bergamaschi R, McCombe P, Sanchez-Menoyo J, Simo M, Csepany T, Rum G, Boz C, Havrdova E, Butzkueven H, MSBase Study Group.
    Ann Neurol; 2015 Mar; 77(3):425-35. PubMed ID: 25546031
    [Abstract] [Full Text] [Related]

  • 22. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
    Bergvall N, Petrilla AA, Karkare SU, Lahoz R, Agashivala N, Pradhan A, Capkun G, Makin C, McGuiness CB, Korn JR.
    J Med Econ; 2014 Oct; 17(10):696-707. PubMed ID: 25019581
    [Abstract] [Full Text] [Related]

  • 23. Is there a change of paradigm towards more effective treatment early in the course of apparent high-risk MS?
    Fernández Ó.
    Mult Scler Relat Disord; 2017 Oct; 17():75-83. PubMed ID: 29055479
    [Abstract] [Full Text] [Related]

  • 24. The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review.
    Biolato M, Bianco A, Lucchini M, Gasbarrini A, Mirabella M, Grieco A.
    CNS Drugs; 2021 Aug; 35(8):861-880. PubMed ID: 34319570
    [Abstract] [Full Text] [Related]

  • 25. [Development of new therapies for multiple sclerosis].
    Holmøy T, Celius EG.
    Tidsskr Nor Laegeforen; 2011 May 06; 131(8):832-6. PubMed ID: 21556088
    [Abstract] [Full Text] [Related]

  • 26. Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.
    Warnke C, Wiendl H, Hartung HP, Stüve O, Kieseier BC.
    Drug Des Devel Ther; 2010 Jul 21; 4():117-26. PubMed ID: 20689698
    [Abstract] [Full Text] [Related]

  • 27. Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches.
    Berardi A, Siddiqui MK, Treharne C, Harty G, Wong SL.
    Curr Med Res Opin; 2019 Aug 21; 35(8):1371-1378. PubMed ID: 30786783
    [Abstract] [Full Text] [Related]

  • 28. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
    Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, Montalban X, Pelletier J, Stites T, Wu S, Holdbrook F, Zhang-Auberson L, Francis G, Cohen JA, TRANSFORMS Study Group.
    Lancet Neurol; 2011 Jun 21; 10(6):520-9. PubMed ID: 21571593
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.
    Vermersch P, Martinelli V, Pfleger C, Rieckmann P, Alonso-Magdalena L, Galazka A, Dangond F, Phillips L.
    Clin Ther; 2019 Feb 21; 41(2):249-260.e18. PubMed ID: 30846120
    [Abstract] [Full Text] [Related]

  • 31. Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon beta-1a in patients with multiple sclerosis.
    Agashivala N, Kim E.
    Clin Ther; 2012 Jul 21; 34(7):1583-90. PubMed ID: 22749258
    [Abstract] [Full Text] [Related]

  • 32. Substantial and comparable suppression of disease activity following early initiation of cladribine tablets, ocrelizumab or alemtuzumab as first pharmacologic treatment for relapsing multiple sclerosis: A real world study.
    Alroughani R, Al-Hashel J, Ahmed SF.
    Clin Neurol Neurosurg; 2024 May 21; 240():108249. PubMed ID: 38513425
    [Abstract] [Full Text] [Related]

  • 33. Update on disease-modifying therapies for multiple sclerosis.
    Vargas DL, Tyor WR.
    J Investig Med; 2017 Jun 21; 65(5):883-891. PubMed ID: 28130412
    [Abstract] [Full Text] [Related]

  • 34. Quantifying the administration and monitoring time burden of several disease-modifying therapies for relapsing multiple sclerosis in the United Kingdom: A time and motion study.
    Rog D, Brownlee W, Carod-Artal FJ, Kalra S, Barker N, Lowndes C, Pendlebury J, Leclerc S, Amin A, Ashton L, Evans H, De Cock E.
    Mult Scler Relat Disord; 2024 Feb 21; 82():105380. PubMed ID: 38183696
    [Abstract] [Full Text] [Related]

  • 35. [Update on current care guidelines: multiple sclerosis].
    Duodecim; 2013 Feb 21; 129(5):548-9. PubMed ID: 23520898
    [Abstract] [Full Text] [Related]

  • 36. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
    Hettle R, Harty G, Wong SL.
    J Med Econ; 2018 Jul 21; 21(7):676-686. PubMed ID: 29618273
    [Abstract] [Full Text] [Related]

  • 37. [The experience of using fingolimod (gilenya) in patients with relapsing-remitting multiple sclerosis].
    Kotov SV, Fedorova SI, Iakushina TI, Lizhdvoĭ VIu.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013 Jul 21; 113(2 Pt 2):74-8. PubMed ID: 23528598
    [Abstract] [Full Text] [Related]

  • 38. [Dilemma of further therapeutic step in remitting-relapsing multiple sclerosis in case of ineffectiveness of first-line treatment: fingolimod or natalizumab?].
    Gábor L.
    Ideggyogy Sz; 2014 Mar 30; 67(3-4):141. PubMed ID: 26118259
    [No Abstract] [Full Text] [Related]

  • 39. Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial.
    Brittain G, Petrie J, Duffy KEM, Glover R, Hullock K, Papaioannou D, Roldan E, Beecher C, Bursnall M, Ciccarelli O, Coles AJ, Cooper C, Giovannoni G, Gabriel I, Kazmi M, Kyriakou C, Nicholas R, Paling D, Peniket A, Scolding N, Silber E, de Silva T, Venneri A, Walters SJ, Young C, Muraro PA, Sharrack B, Snowden JA, StarMS trial team.
    BMJ Open; 2024 Feb 05; 14(2):e083582. PubMed ID: 38316583
    [Abstract] [Full Text] [Related]

  • 40. Drugs in development for relapsing multiple sclerosis.
    Ali R, Nicholas RS, Muraro PA.
    Drugs; 2013 May 05; 73(7):625-50. PubMed ID: 23609782
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.